SLDB
Price
$6.00
Change
+$0.08 (+1.35%)
Updated
Sep 26, 02:29 PM (EDT)
Capitalization
460.98M
SYRE
Price
$16.38
Change
+$0.77 (+4.93%)
Updated
Sep 26, 01:26 PM (EDT)
Capitalization
942.86M
41 days until earnings call
Interact to see
Advertisement

SLDB vs SYRE

Header iconSLDB vs SYRE Comparison
Open Charts SLDB vs SYREBanner chart's image
Solid Biosciences
Price$6.00
Change+$0.08 (+1.35%)
Volume$2.88K
Capitalization460.98M
Spyre Therapeutics
Price$16.38
Change+$0.77 (+4.93%)
Volume$180
Capitalization942.86M
SLDB vs SYRE Comparison Chart in %
Loading...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SLDB vs. SYRE commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLDB is a StrongBuy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (SLDB: $5.92 vs. SYRE: $15.61)
Brand notoriety: SLDB and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLDB: 95% vs. SYRE: 191%
Market capitalization -- SLDB: $460.98M vs. SYRE: $942.86M
SLDB [@Biotechnology] is valued at $460.98M. SYRE’s [@Biotechnology] market capitalization is $942.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLDB’s FA Score shows that 2 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • SLDB’s FA Score: 2 green, 3 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SLDB is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLDB’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • SLDB’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both SLDB and SYRE are a good buy in the short-term.

Price Growth

SLDB (@Biotechnology) experienced а +8.82% price change this week, while SYRE (@Biotechnology) price change was +1.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.36%. For the same industry, the average monthly price growth was +8.66%, and the average quarterly price growth was +50.93%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+3.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($943M) has a higher market cap than SLDB($461M). SLDB YTD gains are higher at: 48.000 vs. SYRE (-32.947). SLDB has higher annual earnings (EBITDA): -152.11M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. SLDB (268M). SYRE has less debt than SLDB: SYRE (0) vs SLDB (23.1M). SLDB (0) and SYRE (0) have equivalent revenues.
SLDBSYRESLDB / SYRE
Capitalization461M943M49%
EBITDA-152.11M-222.15M68%
Gain YTD48.000-32.947-146%
P/E RatioN/A1.72-
Revenue00-
Total Cash268M527M51%
Total Debt23.1M0-
FUNDAMENTALS RATINGS
SLDB vs SYRE: Fundamental Ratings
SLDB
SYRE
OUTLOOK RATING
1..100
911
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4361
P/E GROWTH RATING
1..100
379
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for SYRE (72) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew somewhat faster than SYRE’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew similarly to SYRE’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew similarly to SYRE’s over the last 12 months.

SLDB's Price Growth Rating (43) in the Biotechnology industry is in the same range as SYRE (61) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew similarly to SYRE’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for SYRE (79) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLDBSYRE
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BILPX10.34N/A
N/A
BlackRock Event Driven Equity Instl
TPYAX9.26N/A
N/A
Touchstone Sands Capital Intl Gr Eq A
QCELX22.23N/A
N/A
AQR Large Cap Multi-Style I
GSRFX13.02N/A
N/A
Goldman Sachs Rising Dividend Gr R6
UIVPX12.97N/A
N/A
MFS Intrinsic Value R3

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-8.18%
CGON - SYRE
59%
Loosely correlated
-0.55%
IDYA - SYRE
59%
Loosely correlated
+0.08%
XNCR - SYRE
57%
Loosely correlated
-1.34%
CRNX - SYRE
56%
Loosely correlated
+2.02%
BEAM - SYRE
56%
Loosely correlated
-2.12%
More